Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).

Authors:
Address: Department of Biology, College of Sciences and Mathematics, Stephen F. Austin State University, Nacogdoches, TX 75962, USA.
Journal:

Publication:

abstract

BACKGROUND:

Cryptosporidium parvum causes an opportunistic infection in AIDS patients, and no effective treatments are yet available. This parasite possesses a single fatty acyl-CoA binding protein (CpACBP1) that is localized to the unique parasitophorous vacuole membrane (PVM). The major goal of this study was to identify inhibitors from known drugs against CpACBP1 as potential new anti-Cryptosporidium agents.

METHODS:

A fluorescence assay was developed to detect CpACBP1 activity and to identify inhibitors by screening known drugs. Efficacies of top CpACBP1 inhibitors against Cryptosporidium growth in vitro were evaluated using a quantitative RT-PCR assay.

RESULTS:

Nitrobenzoxadiazole-labelled palmitoyl-CoA significantly increased the fluorescent emission upon binding to CpACBP1 (excitation/emission 460/538 nm), which was quantified to determine the CpACBP1 activity and binding kinetics. The fluorescence assay was used to screen a collection of 1040 compounds containing mostly known drugs, and identified the 28 most active compounds that could inhibit CpACBP1 activity with sub-micromolar IC(50) values. Among them, four compounds displayed efficacies against parasite growth in vitro with low micromolar IC(50) values. The effective compounds were broxyquinoline (IC(50) 64.9 μM), cloxyquin (IC(50) 25.1 μM), cloxacillin sodium (IC(50) 36.2 μM) and sodium dehydrocholate (IC(50) 53.2 μM).

CONCLUSIONS:

The fluorescence ACBP assay can be effectively used to screen known drugs or other compound libraries. Novel anti-Cryptosporidium activity was observed in four top CpACBP1 inhibitors, which may be further investigated for their potential to be repurposed to treat cryptosporidiosis and to serve as leads for drug development.

Related Articles
Functional characterization of a fatty acyl-CoA-binding protein (ACBP) from the apicomplexan Cryptosporidium parvum.
Microbiology. 2006
Functional characterization of a fatty acyl-CoA-binding protein (ACBP) from the apicomplexan Cryptosporidium parvum.
Zeng B, Cai X, Zhu G. Microbiology. 2006 Aug; 152(Pt 8):2355-63.
A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.
PLoS Negl Trop Dis. 2010
A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.
Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen B. PLoS Negl Trop Dis. 2010 Aug 10; 4(8):e794. Epub 2010 Aug 10.
Review Current progress in the fatty acid metabolism in Cryptosporidium parvum.
J Eukaryot Microbiol. 2004
Review Current progress in the fatty acid metabolism in Cryptosporidium parvum.
Zhu G. J Eukaryot Microbiol. 2004 Jul-Aug; 51(4):381-8.
Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
Antimicrob Agents Chemother. 2...
Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations.
Nelson RG, Rosowsky A. Antimicrob Agents Chemother. 2001 Dec; 45(12):3293-303.
Review Drug treatment and novel drug target against Cryptosporidium.
Parasite. 2008
Review Drug treatment and novel drug target against Cryptosporidium.
Gargala G. Parasite. 2008 Sep; 15(3):275-81.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.